OncoMatch/Clinical Trials/NCT06941272
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Is NCT06941272 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies Patritumab Deruxtecan for malignant neoplasm.
Treatment: Patritumab Deruxtecan — Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of HER3-DXd in children and if they tolerate it * What happens to HER3-DXd in children's bodies over time * If children who receive HER3-DXd have the cancer get smaller or go away
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Rhabdomyosarcoma
Demographics
Prior therapy
Must have received: systemic therapy — RMS or hepatoblastoma
Has progressed after at least 1 prior systemic treatment for RMS or hepatoblastoma and who has no satisfactory alternative treatment option
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Childrens Hospital Los Angeles ( Site 3006) · Los Angeles, California
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016) · Aurora, Colorado
- Yale New Haven Hospital ( Site 3012) · New Haven, Connecticut
- Johns Hopkins All Children's Hospital ( Site 3025) · St. Petersburg, Florida
- University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017) · Iowa City, Iowa
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06941272 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages